Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes

Trial Profile

A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2019 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.
    • 04 Feb 2019 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2022.
    • 04 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top